Equities

Basilea Pharmaceutica AG Allschwil

Basilea Pharmaceutica AG Allschwil

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CHF)41.30
  • Today's Change0.75 / 1.85%
  • Shares traded34.24k
  • 1 Year change+15.52%
  • Beta1.0767
Data delayed at least 15 minutes, as of Nov 22 2024 16:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CHF
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments6085149
Total Receivables, Net586264
Total Inventory262423
Prepaid expenses------
Other current assets, total7.654.765.14
Total current assets152175241
Property, plant & equipment, net21222.92
Goodwill, net------
Intangibles, net0.550.580.63
Long term investments------
Note receivable - long term01.272.39
Other long term assets0.040.070.26
Total assets173221247
LIABILITIES
Accounts payable5.850.1911
Accrued expenses182833
Notes payable/short-term debt000
Current portion long-term debt/capital leases1537124
Other current liabilities, total8.639.336.83
Total current liabilities4875174
Total long term debt9513195
Total debt111169218
Deferred income tax------
Minority interest------
Other liabilities, total403537
Total liabilities183242306
SHAREHOLDERS EQUITY
Common stock131313
Additional paid-in capital1,0421,0371,030
Retained earnings (accumulated deficit)(1001)(1011)(1023)
Treasury stock - common(54)(56)(57)
Unrealized gain (loss)------
Other equity, total(10)(3.79)(22)
Total equity(10)(21)(59)
Total liabilities & shareholders' equity173221247
Total common shares outstanding121212
Treasury shares - common primary issue1.101.141.15
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.